Hyderabad: Suven Life Sciences a Hyderabad based pharmaceutical company received a positive nod from the U.S. Patent office. It has granted product patent (U.S. 7,297,711) to the company and this is its first product patent granted in the U.S.

The granted claims of the patent include the class of selective serotonin receptor affinity compounds discovered by Suven and being developed as therapeutic agents.

According to the invention '711 patent disclosure, the compounds are useful in the treatment of neuro-degenarative disorders like Alzheimer's Parkinson, Schizophrenia and Huntington's.

Suven so far has filed 29 product patent applications covering more than 145 countries. Of these, five patents are granted so far. Several other patent applications from Suven discovery research are in the pipeline that have completed the administrative and technical diligence from the patent
offices from major countries and would be granted shortly, the company stated in a press release.

"We are very pleased by the issuance of this patent to Suven by US Patent office for our drug candidates that are being developed for CNS disorders which targets a $18 billion potential market opportunity," said Venkat Jasti, CEO of Suven.